中国临床药理学杂志2019，Vol.35Issue(7)：725-728,4.DOI:10.13699/j.cnki.1001-6821.2019.07.037
重组人尿激酶原静脉溶栓治疗急性ST段抬高型心肌梗死的研究现状
Research status in thrombolytic therapy using recombinant prourokinase for patients with acute myocardial infarction with ST-segment elvation
张学玉 1阎佳 1刘锐1
作者信息
- 1. 天士力医药集团控股有限公司 研究院 临床医学中心,天津 300410
- 折叠
摘要
Abstract
Recombinant human prourokinase for injection (rhPro-UK) is a specific plasminogen activator, mainly acting on the fibrous protein of the thrombus. rhPro-UK presents ideal clinical therapeutic effect in the treatment of acute ST segment elevation myocardial infarction. In terms of clinical efficacy, rhPro-UK is effective in the treatment of patients with myocardial infarction, and the recanalization rate of blood vessels is more than 70％. In terms of safety, less severe bleeding complications are developed compared with thrombolytic medicine. Therefore, rhPro-UK is at low risk of bleeding. This article reviews the physical and chemical properties, thrombolytic mechanism and clinical research of rh Pro-UK.关键词
尿激酶原/急性ST段抬高型心肌梗死/开通率/尿激酶Key words
prourokinase/acute ST segment elevation myocardial infarction/patency/urokinase分类
医药卫生引用本文复制引用
张学玉,阎佳,刘锐..重组人尿激酶原静脉溶栓治疗急性ST段抬高型心肌梗死的研究现状[J].中国临床药理学杂志,2019,35(7):725-728,4.
